ATOS

Atossa Therapeutics, Inc.

Healthcare
Biotechnology
$25M market cap

Forecast run · Sep 14, 2026Upside rank 77 of 3,136

Model Signal

ForecastQ Daily Probabilities

76.8%

30.6%

48.8%

Analyst Consensus

Recommendation2.20/5 Buy

Last price$2.51

Price target$42.50

Implied move+1593.2%

Analysts5

ForecastQ Portfolios

ATOS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.